Logo image
Antenatal Magnesium and Cerebral Palsy in Preterm Infants
Journal article   Open access   Peer reviewed

Antenatal Magnesium and Cerebral Palsy in Preterm Infants

Deborah G Hirtz, Steven J Weiner, Dorothy Bulas, Michael DiPietro, Joanna Seibert, Dwight J Rouse, Brian M Mercer, Michael W Varner, Uma M Reddy, Jay D Iams, …
The Journal of pediatrics, v 167(4), pp 834-839.e3
Oct 2015
PMID: 26254839
url
https://europepmc.org/articles/pmc4587284View
Accepted (AM)Open Access (License Unspecified) Open

Abstract

Cerebral Hemorrhage - diagnostic imaging Cerebral Palsy - blood Cerebral Palsy - diagnostic imaging Cerebral Palsy - prevention & control Cerebral Ventricles - diagnostic imaging Child, Preschool Cohort Studies Electroencephalography Female Gestational Age Humans Infant Infant, Newborn Infant, Premature Leukomalacia, Periventricular - diagnostic imaging Magnesium Sulfate - therapeutic use Male Maternal Exposure Neuroprotective Agents - therapeutic use Pregnancy Ultrasonography
To evaluate the relationship of maternal antenatal magnesium sulfate (MgSO4) with neonatal cranial ultrasound abnormalities and cerebral palsy (CP). In a randomized trial of MgSO4 or placebo in women at high risk of preterm delivery, up to 3 cranial ultrasounds were obtained in the neonatal period. Images were reviewed by at least 2 pediatric radiologists masked to treatment and other clinical conditions. Diagnoses were predefined for intraventricular hemorrhage, periventricular leukomalacia, intracerebral echolucency or echodensity, and ventriculomegaly. CP was diagnosed at 2 years of age by standardized neurologic examination. Intraventricular hemorrhage, periventricular leukomalacia, intracerebral echolucency or echodensity, and ventriculomegaly were all strongly associated with an increased risk of CP. MgSO4 administration did not affect the risk of cranial ultrasound abnormality observed at 35 weeks postmenstrual age or later. However, for the 82% of infants born at <32 weeks gestation, MgSO4 was associated with a reduction in risk of echolucency or echodensity. The reduction in risk for echolucency explained 21% of the effect of MgSO4 on CP (P = .04), and for echodensity explained 20% of the effect (P = .02). MgSO4 given prior to preterm delivery was associated with decreased risk of developing echodensities and echolucencies at <32 weeks gestation. However, this effect can only partially explain the effect of MgSO4 on CP at 2 years of age. ClinicalTrials.gov: NCT00014989.

Metrics

16 Record Views
42 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Pediatrics
Logo image